Petlife Pharmaceuticals, Inc. (PTLF)

Market Cap	22.21K
Revenue (ttm)	n/a
Net Income (ttm)	-3.71M
Shares Out	222.12M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,111
Average Volume	335,325
Open	0.0001
Previous Close	0.0001
Day's Range	0.0001 - 0.0001
52-Week Range	0.0001 - 0.0010
Beta	57.58
RSI	47.26
Earnings Date	n/a

About Petlife Pharmaceuticals

Petlife Pharmaceuticals, Inc. engages in the research, development, sale, and support of drugs and nutraceuticals for pet cancer and autoimmune related diseases, such as arthritis in the United States. The company’s principal product is Vitalzul that inhibits blood vessels formation in solid tumors. It is also developing Vitalzul as a prescription strength oral pharmaceutical, as well as a concentrated intravenous and injectable version for direct administration to a tumor. In addition, the company develops edible dog and cat treats. Petlife Ph...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Sebastian Serrell-Watts
• Employees: 1
• Stock Exchange: OTCMKTS
• Ticker Symbol: PTLF